RPG Life Sciences Limited (RPGLIFE.NS)
INR 2037.1
(-1.75%)
INR 2037.1
(-1.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.12 Billion INR | 22.3% |
| 2022 | 4.19 Billion INR | 21.69% |
| 2021 | 3.44 Billion INR | 13.59% |
| 2020 | 3.03 Billion INR | 13.74% |
| 2019 | 2.66 Billion INR | 6.17% |
| 2018 | 2.51 Billion INR | -13.74% |
| 2017 | 2.91 Billion INR | 18.27% |
| 2016 | 2.46 Billion INR | 20.0% |
| 2015 | 2.05 Billion INR | 4.23% |
| 2014 | 1.96 Billion INR | 0.43% |
| 2013 | 1.96 Billion INR | -4.71% |
| 2012 | 2.05 Billion INR | 12.5% |
| 2011 | 1.82 Billion INR | -4.19% |
| 2010 | 1.9 Billion INR | 14.06% |
| 2009 | 1.67 Billion INR | -0.33% |
| 2008 | 1.67 Billion INR | -4.27% |
| 2007 | 1.75 Billion INR | -14.63% |
| 2006 | 2.05 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 5.12 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 5.12 Billion INR | 22.3% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 4.61 Billion INR | 0.0% |
| 2022 FY | 4.19 Billion INR | 21.69% |
| 2022 Q4 | 4.19 Billion INR | 0.0% |
| 2022 Q2 | 3.74 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 3.27 Billion INR | 0.0% |
| 2021 Q4 | 3.44 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 3.44 Billion INR | 13.59% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.81 Billion INR | 0.0% |
| 2020 Q4 | 3.03 Billion INR | 0.0% |
| 2020 FY | 3.03 Billion INR | 13.74% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 2.66 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 2.66 Billion INR | 6.17% |
| 2019 Q4 | 2.66 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 2.51 Billion INR | -13.74% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 2.69 Billion INR | 0.0% |
| 2018 Q4 | 2.51 Billion INR | 0.0% |
| 2017 Q4 | 2.91 Billion INR | 0.0% |
| 2017 FY | 2.91 Billion INR | 18.27% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 2.65 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 2.46 Billion INR | 20.0% |
| 2016 Q4 | 2.46 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 2.29 Billion INR | 0.0% |
| 2015 FY | 2.05 Billion INR | 4.23% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 2.09 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 2.05 Billion INR | 0.0% |
| 2014 FY | 1.96 Billion INR | 0.43% |
| 2014 Q4 | 1.96 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 2.04 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q4 | 1.96 Billion INR | 0.0% |
| 2013 FY | 1.96 Billion INR | -4.71% |
| 2013 Q2 | 2.15 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q4 | 2.05 Billion INR | 0.0% |
| 2012 Q2 | 4.12 Billion INR | 0.0% |
| 2012 FY | 2.05 Billion INR | 12.5% |
| 2011 FY | 1.82 Billion INR | -4.19% |
| 2010 FY | 1.9 Billion INR | 14.06% |
| 2009 FY | 1.67 Billion INR | -0.33% |
| 2008 FY | 1.67 Billion INR | -4.27% |
| 2007 FY | 1.75 Billion INR | -14.63% |
| 2006 FY | 2.05 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -68.158% |
| Aarti Drugs Limited | 24.32 Billion INR | 78.915% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 80.137% |
| Ajanta Pharma Limited | 46.38 Billion INR | 88.943% |
| Alembic Limited | 23.28 Billion INR | 77.977% |
| Alkem Laboratories Limited | 155.74 Billion INR | 96.707% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 92.043% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 52.425% |
| Bal Pharma Limited | 3.2 Billion INR | -60.077% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -989.296% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 57.749% |
| Brooks Laboratories Limited | 904.45 Million INR | -467.049% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -247.281% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 80.986% |
| Divi's Laboratories Limited | 154.7 Billion INR | 96.685% |
| Eris Lifesciences Limited | 70.48 Billion INR | 92.724% |
| Granules India Limited | 55.2 Billion INR | 90.711% |
| Ind-Swift Limited | 6.54 Billion INR | 21.636% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -136.261% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 87.159% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 95.559% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -113.641% |
| Medicamen Biotech Limited | 2.94 Billion INR | -74.136% |
| Medico Remedies Limited | 961.95 Million INR | -433.155% |
| Wockhardt Limited | 76.49 Billion INR | 93.295% |
| Orchid Pharma Limited | 15.53 Billion INR | 66.994% |
| Shilpa Medicare Limited | 30.93 Billion INR | 83.419% |
| Sigachi Industries Limited | 6.94 Billion INR | 26.116% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 78.144% |
| Unichem Laboratories Limited | 31.69 Billion INR | 83.818% |
| Vaishali Pharma Limited | 799.55 Million INR | -541.443% |
| Wanbury Limited | 3.43 Billion INR | -49.31% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.248% |
| FDC Limited | 24.68 Billion INR | 79.22% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -39.796% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 32.969% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.677% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 82.007% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 55.981% |
| Laurus Labs Limited | 83.87 Billion INR | 93.885% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -53.819% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 76.593% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -404.738% |
| Hester Biosciences Limited | 6.62 Billion INR | 22.568% |
| Ipca Laboratories Limited | 111.01 Billion INR | 95.38% |
| Venus Remedies Limited | 6.26 Billion INR | 18.18% |
| ZIM Laboratories Limited | 4.46 Billion INR | -14.782% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.862% |
| Morepen Laboratories Limited | 12.93 Billion INR | 60.341% |
| Neuland Laboratories Limited | 18.32 Billion INR | 72.013% |
| Sequent Scientific Limited | 15.4 Billion INR | 66.705% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 77.247% |
| Valiant Laboratories Limited | 3.42 Billion INR | -49.661% |
| Windlas Biotech Limited | 6.26 Billion INR | 18.099% |
| Hikal Limited | 24.87 Billion INR | 79.379% |
| Innova Captab Limited | 13.2 Billion INR | 61.172% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 35.436% |
| Themis Medicare Limited | 5.66 Billion INR | 9.454% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 77.149% |
| Mankind Pharma Limited | 119.63 Billion INR | 95.713% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 96.428% |
| Sakar Healthcare Limited | 3.88 Billion INR | -31.959% |
| Albert David Limited | 4.97 Billion INR | -2.988% |
| Lupin Limited | 239.97 Billion INR | 97.863% |
| Gufic Biosciences Limited | 10.92 Billion INR | 53.057% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.4% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 26.763% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -26.74% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.379% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 96.595% |
| NATCO Pharma Limited | 69.06 Billion INR | 92.574% |
| Suven Life Sciences Limited | 2.84 Billion INR | -80.016% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -187.847% |
| Strides Pharma Science Limited | 58.39 Billion INR | 91.218% |
| Indoco Remedies Limited | 21.44 Billion INR | 76.087% |
| Alpa Laboratories Limited | 1.82 Billion INR | -180.837% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -239.945% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 0.421% |